Early clinical symptoms of sporadic Creutzfeldt-Jakob disease (CJD) may overlap with other neurodegenerative diseases like Alzheimer's disease (AD) and frontotemporal degeneration (FTD). On entering an era in which pharmaceutical treatment of CJD occurs, reliable diagnostic markers like immunodetection of 14-3-3 proteins in the cerebrospinal fluid (CSF) are required. However, false negative results in autopsy-proven, sporadic CJD cases, as well as false positive results in several other disorders including AD and FTD showing high CSF tau protein levels, limit the potential of this marker. Due to neuronal lysis the cytosolic fraction of total tau containing phosphorylated and non-phosphorylated isoforms is partially liberated into the CSF. Since hyperphosphorylation of tau may specifically occur in neurodegenerative diseases associated with neurofibrillary changes, we hypothesized that the phospho-tau (P-tau)/total tau ratio in CSF may be a useful marker to discriminate CJD from other neurodegenerative disorders. The P-tau/total tau ratio discriminated patients with CJD from all other neurodegenerative disorders including patients with AD and FTD without any overlap. Although the results have to be confirmed in a larger sample, the preliminary data suggest that simultaneous measurement of total tau and P-tau in CSF may be useful to identify patients with CJD.
Introduction
Sporadic Creutzfeldt-Jakob disease (CJD) is characterized by progressive dementia, pyramidal dysfunction, myoclonus, extrapyramidal signs, visual symptoms, and ataxia. Heterogeneity of symptoms, especially early in the course of disease, may lead to an overlap with other frequent neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal degeneration (FTD). To improve clinical accuracy, immunodetection of 14-3-3 proteins in the cerebrospinal fluid (CSF) has shown a high sensitivity and specificity for CJD. 1 However, recent research revealed that there are false negative results in some typical, autopsy-proven, sporadic CJD cases, 1,2 as well as false positive results in several other disorders including AD and FTD showing high CSF tau protein levels. 3 Tau proteins are highly abundant within the cytosol of neurons and physiologically promote microtubule assembly. In AD, tau proteins get hyperphosphorylated, because of an imbalance of cellular kinases and phosphatases, subsequently accumulate within the cytosol, and form neurofibrillary tangles (NFT) after some post-translational modifications. As a result of neuronal lysis, the cytosolic fraction of total tau containing phosphorylated and non-phosphorylated isoforms 4 is liberated into the extracellular space and partially appears in the CSF. CSF total tau concentrations may reflect the extent of the neurodegenerative process since levels were extraordinarily high in CJD, 5 followed by AD 6 and FTD. 7 Since hyperphosphorylation of tau proteins and NFTs are not present in CJD, we hypothesized that measurement of phosphorylated tau (P-tau) or the ratio between P-tau and total tau may improve separation between CJD, AD, and FTD.
Methods
The study refers to 109 demented outpatients that were referred to a university hospital or memory clinic for diagnostic evaluation and who met the following diagnostic criteria: AD-NINCDS-ADRDA 8 (n ¼ 71), FTD-consensus criteria 9 (n ¼ 18), CJD according to established criteria 10 (n ¼ 20). Clinical diagnosis of CJD was confirmed by neuropathological examination in 10 cases. We also included 43 cognitively healthy controls. The groups are described in greater detail in Table 1 . The diagnostic work-up included a thorough psychiatric and neurologic evaluation, a chemistry survey, an informant interview, and a cognitive examination using Consortium to Establish a Registry of Alzheimer's disease neuropsychological battery 11 that incorporates the Mini Mental State Examination (MMSE). The MMSE was used to test cognitive ability in control subjects. In each patient structural MRI imaging and in subjects with AD and FTD additional functional imaging using 18 FDG PET was performed. Visual rating of functional images helped to classify patients with FTD as every patient with FTD had markedly frontal or anterior temporal hypometabolism. To improve diagnostic accuracy, patients with FTD were reexamined by an independent psychiatrist according to the consensus criteria 9 2-3 years later in the course of the disease. The prior diagnosis was confirmed in all patients. Spinal taps of all subjects were performed in the morning after informed written consent had been obtained. CSF (5-8 ml) of all patients was collected in sterile polypropylene tubes and gently mixed to avoid gradient effects. Serum was obtained by venous puncture. In native CSF, routine chemical parameters including a CSF to serum ratio of albumin and immunoglobulin G, and a screening for oligoclonal bands were determined. The remaining CSF was centrifuged for 10 min at 4000 g, and supernatants were aliquoted and stored at À801C for subsequent total tau and P-tau determination. CSF P-tau levels were measured as described previously 12 using HT7 as the capturing antibody in combination with AT270 as the detector antibody in a double-antibody sandwich ELISA. The HT7 recognizes all tau isoforms irrespective of their phosphorylation status. The AT270 is specific for the threonine 181 phosphorylation site. A synthetic phosphopeptide (sequence: R 154 -T 187 ; Thr 181 P) was included as standard. The detection limit of this assay was 2.5 ng/l. 12 In addition, the CSF total tau content was measured by ELISA (Innotest hTau-Ag; Innogenetics, Ghent, Belgium) as described elsewhere. 13 All samples were run on three consecutive days. All statistical procedures were performed using the Statistical Package of the Social Sciences (SPSS) software. Data are presented as median with the 25 and 75 percentile in brackets (p25-p75), since tau and P-tau values were not distributed normally. Correlations were calculated using Spearman's two-tailed correlation test. For twogroup comparisons, Mann-Whitney U-tests were used; and for three-group comparisons, KruskalWallis and Nemenyi tests were used. Considering the multiple testing situations, any of the P-values were significant on a global two-sided 5% significance level. In addition, multiple ANOVA, with P-tau as the dependent variable and total tau, age, age of onset, sex, apoE, and MMSE as covariates, was performed.
Results
The CSF content of P-tau was significantly increased in AD, even in 22 patients with very mild AD (MMSEX25) compared to CJD (Po0.001), FTD (P ¼ 0.001), and cognitively normal controls (Po0.001). P-tau concentrations were higher in Data concerning P-tau, total tau, and the P-tau/total tau ratio are given as median with 25 and 75 percentiles in parentheses in the first line and as range in the second line. The MMSE was not available for all patients with CJD.
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Although there was some overlap between CJD and AD, total tau concentrations were higher in patients with CJD than in AD (Po0.001), FTD (Po0.001), and controls (Po0.001). In addition, total tau concentrations were also significantly elevated in AD compared to FTD (Po0.001). Total tau levels of both groups, AD and FTD, were higher than in controls (Po0.001) ( Table 1) .
The P-tau/total tau ratio was lowest in patients with CJD followed by patients with FTD, AD, and controls (for all comparisons Po0.001), showing no overlap with any other diagnostic group (Figure 2 ). No significant difference was obtained between patients with AD and FTD, but both ratios were lower as compared to controls (AD: P ¼ 0.003; FTD: P ¼ 0.001).
Within AD, CSF P-tau and total tau concentrations were independent of the severity of dementia. Also, CSF P-tau concentration was unrelated to age, sex, and cognitive ability as assessed using the MMSE. Exclusively in the AD group, P-tau and total tau were intimately associated (r ¼ 0.87; Po0.001), which was not seen in any other diagnostic group.
Discussion
We have measured P-tau and total tau concentrations in the CSF and calculated the P-tau/total tau ratio in clinically well-described patients with AD, FTD, and CJD. A major limitation of all studies trying to evaluate diagnostic markers in clinically defined patient samples is the probability of incorrect clinical classification. For CJD and FTD, this probability may be greater than for typical AD. In this study we tried to minimize this issue by re-examination of patients with FTD approximately 2-3 years later in the course of the disease and by autopsy in half of our patients with CJD. Despite all efforts, autopsy data were not available for the other half of patients with CJD.
We found highest P-tau concentrations in patients with AD followed by patients with CJD and FTD, and the lowest concentrations in cognitively healthy controls. Although there was an overlap of total tau levels between CJD and AD, they were highest in CJD, followed by AD and FTD, and lowest in controls. As hypothesized, calculation of the P-tau/total tau ratio separated patients with CJD from AD and FTD without overlap. This finding will probably improve clinical diagnosis of CJD at least with regard to the separation from patients with AD and FTD. The reason for the decreased P-tau/total tau ratio in patients with CJD is not clear. However, the data suggest that elevated P-tau concentrations in CSF may reflect a higher degree of tau phosphorylation, which may be associated with neurofibrillary pathology, 14 as present in patients with AD. Thus, the significantly lower P-tau concentrations in CJD may reflect a lower extent of phosphorylation at the threonine 181 residue, which corresponds to neuropathological data indicating that NFTs are usually absent in sporadic Phospho-tau in CSF M Riemenschneider et al CJD. By contrast, the rapid neurodegenerative process including axonal degeneration in CJD leads to an excessive liberation of tau proteins, which causes the low P-tau/total tau ratio. Differences in P-tau concentrations of patients with FTD may also be related to the presence of NFT pathology. 14 This view is supported by our observation that three patients with FTD and Parkinsonism, which has been associated with neurofibrillary changes and tau mutations, 15 showed high P-tau concentrations. The low P-tau levels in controls showed only very small variability, which may be caused by a bottom effect of the applied ELISA.
The high correlation between tau and P-tau in patients with AD may indicate the common neuronal origin of both proteins and may be associated with the presence of NFTs since no correlation was observed in patients with FTD where tau pathology is infrequent. 16 In addition, the higher CSF levels of P-tau compared to total tau found in this and other studies 12, 17, 18 may be caused by the application of different standards. A synthetic peptide was used in P-tau and a recombinant protein for the total tau ELISA. As described, the relative amount of P-tau in CSF may be calculated by dividing the P-tau/total tau ratio by 4.3, a correction factor that has been determined previously. 12 Our results of increased P-tau concentrations in patients with AD and lower concentrations in FTD are consistent with previous studies that applied the same antibodies 12, 17 or used antibodies against other phosphorylated tau epitopes.
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Conclusion
In conclusion, the present study provides evidence that simultaneous measurement of CSF P-tau and total tau with calculation of the P-tau/total tau ratio may be useful for discriminating patients with CJD from patients with AD and FTD. Future studies including patients with the new variant of CJD, which are currently not available in Germany, are required for further validation. Figure 2 Scatter of P-tau/total tau ratios by diagnostic groups.
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